Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine (IRON) director reported open‑market sales of common stock on 10/15/2025–10/17/2025. Transactions were executed in multiple tranches at weighted‑average prices, including ranges from $76.75–$77.60 and up to $92.15.
Following the sales, indirect holdings reported were 442,036 shares held by Atlas Venture Opportunity Fund I, LP; 385,549 shares held by Atlas Venture Opportunity Fund II, LP; and 51,000 shares held by Atlas Venture Fund XII, L.P. The reporting person is a member of the respective general partners and disclaims beneficial ownership beyond any pecuniary interest.
Disc Medicine (IRON) reported receiving a Commissioner’s National Priority Voucher (CNPV) from the U.S. FDA for bitopertin in erythropoietic protoporphyria (EPP), including X‑linked protoporphyria. The company previously submitted a New Drug Application in September 2025 for patients aged 12 and older under the FDA’s accelerated approval pathway.
The CNPV program, announced in June 2025, is intended to speed development and review of drugs tied to U.S. national health priorities. A CNPV provides benefits such as enhanced communications and rolling review, with the opportunity to reduce application review times to one to two months. This update highlights a potential pathway for a shortened FDA review of bitopertin after the NDA submission.
Director Kevin Bitterman reported a series of open-market sales of Disc Medicine, Inc. common stock executed on 10/07/2025 and 10/08/2025. The filings show 90,000 shares sold across multiple transactions at weighted average prices ranging roughly from $68.00 to $72.62, reducing his reported indirect beneficial holdings to 500,621 shares held through affiliated Atlas Venture funds. The sales are disclosed under Section 16 and were signed by an attorney-in-fact on 10/09/2025. The report identifies the holdings as indirect via Atlas Venture entities and includes footnotes describing the fund ownership structure and weighted-average price ranges for each tranche sold.
Form 144 notice indicates an intended sale of 71,961 shares of common stock by an affiliate, to be executed through Merrill Lynch on 10/08/2025 on Nasdaq. The filing shows those shares were acquired on 05/01/2020 in a private placement and paid in cash. The filing reports an aggregate market value of $4,885,432.29 for the shares and discloses 34,765,581 shares outstanding. The record of recent sales lists multiple transactions by related Atlas Venture funds from 07/18/2025 through 10/07/2025, showing ongoing dispositions by affiliated holders.
Disc Medicine, Inc. (IRON) notice reports a proposed sale of 18,039 common shares with an aggregate market value of $1,249,741.90, scheduled for 10/07/2025 on Nasdaq. The shares were acquired in a private placement on 05/01/2020 and were paid in cash. The filing shows the issuer has 34,765,581 shares outstanding, so the proposed sale represents a small percentage of total shares. Recent related activity shows multiple secondary sales by affiliated Atlas Venture funds between 07/18/2025 and 08/22/2025, including several large blocks (for example, 53,215 shares sold on 07/23/2025 for $3,244,656.91), indicating ongoing monetization by those funds.
Disc Medicine, Inc. reported that board member Mona Ashiya, Ph.D., a Class I director, resigned from its Board of Directors effective October 3, 2025. She also stepped down from the Board’s Compensation Committee and Nominating and Corporate Governance Committee. The company stated that her resignation was not due to any disagreement with Disc Medicine regarding its operations, policies, or practices. Following her departure, the size of the Board was reduced from nine members to eight.
Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.
This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.
Georges Gemayel, a director of Disc Medicine, Inc. (ticker: IRON), was granted a stock option to purchase 1,000 shares of common stock on 09/16/2025 at an exercise price of $60.34 per share. The option is exercisable subject to vesting that occurs on the earlier of the company’s 2026 annual meeting or the one-year anniversary of the grant date, and it expires on 09/15/2035. The filing reports the option as a direct holding and shows 1,000 underlying shares following the transaction.
This Form 4 was submitted by an attorney-in-fact and signed on behalf of the reporting person on 09/18/2025. No other transactions or cash sales are disclosed in the filing.
John D. Quisel, who serves as Chief Executive Officer and a director of Disc Medicine, Inc. (IRON), reported two related transactions dated 09/09/2025. He acquired 10,000 shares of common stock at $1.01 per share, bringing his total direct common stock holdings to 171,828 shares. On the same date he was granted or reported a stock option to buy 10,000 shares with an exercise price of $1.01, exercisable immediately and expiring 03/10/2030, increasing his total beneficial ownership including derivatives to 198,420 shares. The filing states the optioned shares are fully vested and exercisable as of the report date.
Kevin Bitterman, a director of Disc Medicine, Inc. (ticker: IRON), reported a sale of company stock under a pre-existing trading plan. On 08/22/2025 he sold 2,287 shares of common stock pursuant to a Rule 10b5-1 trading plan dated January 31, 2025, at a weighted average price of $61.03 per share (individual sale prices ranged from $60.95 to $61.05). The reporting person says he can provide a breakdown of shares sold at each price on request.
The report shows beneficial ownership held indirectly through Atlas-related investment vehicles: 590,621 shares in Atlas Venture Opportunity Fund I, LP; 420,549 shares in Atlas Venture Opportunity Fund II, LP; and 51,000 shares in Atlas Venture Fund XII, L.P. The filer disclaims beneficial ownership of those fund-held shares except to the extent of any pecuniary interest.
Form 144 filed for Disc Medicine, Inc. (IRON) reports a proposed sale of 2,287 shares of Common Stock through Merrill Lynch, with an aggregate market value of $136,648.25 and an approximate sale date of 08/22/2025 on Nasdaq. The shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date. The filer reports no securities sold during the past three months for the account. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption language.